Jennifer Good compensation by year
Trevi Therapeutics Summary Compensation Table · all 8 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Salary | $400,000 | $434,615 | $477,692 | $505,961 | $523,182 | $596,924 | $607,930 | $622,382 |
| Bonus | $120,000 | $144,900 | $176,400 | $216,750 | $249,518 | $229,075 | $368,974 | $343,750 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Option awards | $0 | $2,222,804 | $778,815 | $796,028 | $116,245 | $851,399 | $1,601,781 | $2,968,260 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $8,250 | $8,400 | $8,550 | $8,700 | $9,150 | $9,900 | $10,350 | $10,500 |
| Total | $528,250 | $2,810,719 | $1,441,457 | $1,527,439 | $898,095 | $1,687,298 | $2,589,035 | $3,944,892 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Trevi Therapeutics, Inc. DEF 14A filed April 21, 2026, accession 0001193125-26-166695, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Trevi Therapeutics, Inc. filed document, accession 0001193125-26-166695. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 341,250 | — | $2.38 |
| Option | 11,459 | — | $0.51 |
| Option | 109,375 | — | $2.67 |
| Option | 811,000 | — | $4.22 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Trevi Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Trevi Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jennifer Good · this page | President and Chief Executive Officer | $3,944,892 |
| James Cassella | Chief Development Officer | $1,637,220 |
| Farrell Simon | Chief Commercial Officer | $1,355,897 |
Board service
Trevi Therapeutics board · FY2021–FY2025How this board is paid
Company policy: Trevi Therapeutics pays directors a $40,000 cash retainer. As stated in Trevi Therapeutics's FY2025 proxy.
The full Trevi Therapeutics compensation record
free company briefThis page is one person within Trevi Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Trevi Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Trevi Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Trevi Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order TRVI
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.